Trials / Completed
CompletedNCT01635517
Efficacy and Safety of Tolvaptan in Japanese Patients With Acute Heart Failure
Multicenter Tolvaptan Study For Uncontrolled Volume Overload in Japanese Acute Decompensated Heart faIlure Patients: A Prospective Observational Multicenter Cohort Study
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 274 (actual)
- Sponsor
- Translational Research Center for Medical Innovation, Kobe, Hyogo, Japan · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
The aims of the present study are to investigate prospectively the clinical course and outcome of the hospitalized heart failure patients treated with tolvaptan for management of fluid retention and serum sodium levels of less than 140 mEq/L and also to analyze the factors related with the efficacy including outcome of tolvaptan therapy.
Detailed description
Vasopressin mediates fluid retention in heart failure. Tolvaptan, an oral, nonpeptide, selective vasopressin V2-receptor antagonist, shows promise for management of heart failure.
Conditions
Timeline
- Start date
- 2012-07-01
- Primary completion
- 2015-12-31
- Completion
- 2015-12-31
- First posted
- 2012-07-09
- Last updated
- 2017-06-02
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT01635517. Inclusion in this directory is not an endorsement.